{"name":"Agile Therapeutics","slug":"agile","ticker":"AGRX","exchange":"NASDAQ","domain":"agiletherapeutics.com","description":"Agile Therapeutics is a women's healthcare company focused on developing and commercializing innovative prescription therapies for women. The company's lead product, Twirla, is a low-dose, weekly contraceptive patch. Agile Therapeutics is a relatively small player in the women's healthcare market, with a limited product portfolio and a focus on niche indications.","hq":"Princeton, NJ","founded":0,"employees":"","ceo":"Al Altomari","sector":"Women\\","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":19593000,"revenueGrowth":80,"grossMargin":0,"rdSpend":2225000,"netIncome":-14465000,"cash":10255000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2035-06-01","label":"Twirla patent cliff ($100M at risk)","drug":"Twirla","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Levora","genericName":"Levora","slug":"levora","indication":"Other","status":"marketed"},{"name":"levonorgestrel and ethinyl estradiol","genericName":"levonorgestrel and ethinyl estradiol","slug":"levonorgestrel-and-ethinyl-estradiol","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Levora","genericName":"Levora","slug":"levora","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"levonorgestrel and ethinyl estradiol","genericName":"levonorgestrel and ethinyl estradiol","slug":"levonorgestrel-and-ethinyl-estradiol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Agile Therapeutics Announces FDA Approval of Twirla","summary":"The FDA approved Twirla, a low-dose, weekly contraceptive patch, for the prevention of pregnancy in women of reproductive age.","drugName":"Twirla","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Agile Therapeutics Reports Third Quarter 2023 Financial Results","summary":"The company reported a net loss of $13.4 million for the third quarter of 2023, compared to a net loss of $14.1 million for the same period in 2022.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLWFHQXY1VTktNTZSX0RLTXpQTWhCQWN4UXFlZEtySl9tSmg2ZFRrZHpzYU1SWnJpdFVZRnlpZkNqb2xiVVNtYVlqOFJUd0NOYjZCVWt0YWd3enMtdzlWZEQxSUhjWDFBRGNWNUtQS3ZGZXlfSWlFYlZQY0NRNFFWSXZXOVBLbmFpTThlaXdfOEpKNGI4aF9qZVM1NUE5RU5DVDZoQWVfN1ctVjBHRG5yV0V5RTdMUUI4VW1OTGNjWDEyelprZjNFRmtzS3ZBRFM0aHdLbzFlOTdCWUpXakV3YWFhRnk1TTh1eVE?oc=5","date":"2024-08-26","type":"pipeline","source":"GlobeNewswire","summary":"Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L. - GlobeNewswire","headline":"Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOVkx2dUN0VU0yeGhER1JDYlZrdjVnblZRM041Y2xyUTE2X1diOTEwaHpkUHBzbzlpdDBBMXYwY05RZGgxNHhUS3dTTjJjNXRUZ1JNeXE4YjRkUHF2R1JGTUpyYlI1bTQ2WEpCdlBKYXhEZTFCSTZ4c1F0U0REM3pqYTNRdVJtOE0zUUZILU9memlSU3BTQUhrZlowQk9rVFV0d2gwN093UkFVMnVUNWx4QzFxYnJfWkZMWjh5YmRIbEZPQWEyM1Z2Zkt0Z3FOQmZkVjhQbXZJYlFHbUp2YWZHUXJoeTNYZzN1LWdzdFN0dw?oc=5","date":"2024-06-26","type":"deal","source":"GlobeNewswire","summary":"Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L. - GlobeNewswire","headline":"Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQdmV6XzJtUmhUS3AteWVXLUptc1dhdlczMUlSdzJmbnNZSGs0NUpqYXdSWjZobU5OVS1nY2ZvZnl1bU9GQnNQN19qb1ZMY3dnR1cyQlMtR2VMS0xRMW1fdW9URzdkM0Z6SURnbHR6ZXdINkJSYTdyYnIxdldEQ1VOMnRuOXlSdGNYdnpvYnNDaFlaRk5vUE1SdnZXWnlyZWhPM3o0ZjlDRGxqazNpOWhQTVB6aVlhRGpvd1lyWmZZQjI?oc=5","date":"2024-03-21","type":"earnings","source":"Stock Titan","summary":"Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024 - Stock Titan","headline":"Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Updat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPN1YwQUZ5LTlMVENwWm5mSGh5a01QclVzV20xS0d5SElyTzEyaDBGUnkxbE94VWljVHpSWlAydXQ2VmZpSmlJaDhVMFVpU2ZIRUVkaEhGYUZEZTdmMXhYMk1uOTBFTEdXRmllQldmZEtBMjlwb0JmbVN4Q0tHRXVKZHFOM3o0MVRnbzZMdkUxN050YW8?oc=5","date":"2023-01-18","type":"pipeline","source":"citybiz","summary":"Corium Pharma Solutions Appoints Mark Sirgo As CEO - citybiz","headline":"Corium Pharma Solutions Appoints Mark Sirgo As CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPUGZQMjMwTEdLbGx2b3ppOFlXODJwTnNyWDdNenB0TFh6a2JKQVpjZFFhRDJ2UHg0RHhWRF9tekJTRnd2aWlYaUJxeGxyMmlaQU1YS2xnX2FzV193ODA3OF9NTXRXazZZczdFSVNQNjNDdWFXSHBKY1VhczVNYk8tMmFzR0NRWV9xdnhhMXF2aVYyMkRYM1VvUW15YWg?oc=5","date":"2022-04-27","type":"pipeline","source":"asktraders.com","summary":"Agile Therapeutics Stock Falls 20% On A 3,300% Price Rise – What? - asktraders.com","headline":"Agile Therapeutics Stock Falls 20% On A 3,300% Price Rise – What?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE15N3RNaFdhZDQycWxhajc5RGtuYmd2aTR1WWhJMlVObzI4ejY4bEpBVUo1MXlhOG1MeG50aFJpTkoxZnRjdWhMc1dHd3VLQQ?oc=5","date":"2020-09-02","type":"pipeline","source":"Stock Titan","summary":"Latest AGRX News - Agile Therapeutics Inc. Announces Completio... - Stock Titan","headline":"Latest AGRX News - Agile Therapeutics Inc. Announces Completio...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9oQlFkOWRDbmgxeE4zLVppanJGcFhWY0NoSzhvaU1HZ0t2RjZfMTJDRDRqUWJKVzRFSm5hTEVMZVYzSDFoajVJNWNqOWZSVmlBd19wT3NxWnNOQQ?oc=5","date":"2015-09-07","type":"pipeline","source":"MarketBeat","summary":"Agile Therapeutics (AGRX) Stock Price, News & Analysis - MarketBeat","headline":"Agile Therapeutics (AGRX) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"Twirla","drugSlug":"estradiol-and-levonorgestrel","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":100000000}],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Allergan","Bayer","Merck"],"therapeuticFocus":["Women's Health","Contraception"],"financials":{"source":"sec_edgar","revenue":19593000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":19593000,"period":"2023-12-31"},{"value":10884000,"period":"2022-12-31"},{"value":10884000,"period":"2022-12-31"},{"value":6888000,"period":"2022-09-30"},{"value":3002000,"period":"2022-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":2225000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-14465000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":10255000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}